ABSTRACT
PURPOSE: The purpose of this study was to characterize the phenotype associated with a de novo gain-of-function variant in the GUCY1A2 gene. METHODS: An individual carrying the de novo heterozygous variant c.1458G>T p.(E486D) in GUCY1A2 was identified by exome sequencing. The effect of the corresponding enzyme variant α2E486D/ß1 was evaluated using concentration-response measurements with wild-type enzyme and the variant in cytosolic fractions of HEK293 cells, UV-vis absorbance spectra of the corresponding purified enzymes, and examination of overexpressed fluorescent protein-tagged constructs by confocal laser scanning microscopy. RESULTS: The patient presented with precocious peripheral puberty resembling the autonomous ovarian puberty seen in McCune-Albright syndrome. Additionally, the patient displayed severe intellectual disability. In vitro activity assays revealed an increased nitric oxide affinity for the mutant enzyme. The response to carbon monoxide was unchanged, while thermostability was decreased compared to wild type. Heme content, susceptibility to oxidation, and subcellular localization upon overexpression were unchanged. CONCLUSION: Our data define a syndromic autonomous ovarian puberty likely due to the activating allele p.(E486D) in GUCY1A2 leading to an increase in cGMP. The overlap with the ovarian symptoms of McCune-Albright syndrome suggests an impact of this cGMP increase on the cAMP pathway in the ovary. Additional cases will be needed to ensure a causal link.
Subject(s)
Fibrous Dysplasia, Polyostotic , Puberty, Precocious , Female , Humans , Fibrous Dysplasia, Polyostotic/diagnosis , Gain of Function Mutation , HEK293 Cells , Ovary , Puberty, Precocious/etiologyABSTRACT
Two-dimensional separations provide a simple way to increase the resolution and peak capacity of complex protein separations. The feasibility of a recently developed instrumental approach for two-dimensional separations of proteins was evaluated. The approach is based on the general principle of two-dimensional gel electrophoresis. In the first dimension, semi-preparative strong anion exchange high-performance liquid chromatography is utilized and fractions are collected by means of a fraction collector. They are subsequently analyzed in the second dimension with microchip capillary electrophoresis sodium dodecyl sulfate. Microchip capillary electrophoresis provides the necessary speed (approximately 1 min/fraction) for short analysis. In this study, three different samples were investigated. Different constructs of soluble guanylyl cyclase were expressed in Sf9-cells using the baculovirus expression system. Cell lysates were analyzed and the resulting separations were compared. In our experimental setup, the soluble guanylyl cyclase was identified among hundreds of other proteins in these cell lysates, indicating its potential for screening, process control, or analysis. The results were validated by immunoblotting. Samples from Chinese hamster ovary cell culture before and after a purification step were investigated and approximately 9% less impurities could be observed. The separation patterns obtained for human plasma are closely similar to patterns obtained with two-dimensional gel electrophoresis and a total of 218 peaks could be observed. Overall, the approach was well applicable to all samples and, based on these results, further directions for improvements were identified. .
Subject(s)
Chromatography, Ion Exchange/instrumentation , Electrophoresis, Capillary/instrumentation , Proteins/isolation & purification , Animals , Anions/chemistry , CHO Cells , Chromatography, High Pressure Liquid/instrumentation , Cricetulus , Humans , Sodium Dodecyl Sulfate/chemistryABSTRACT
Soluble guanylyl cyclase (sGC), the major receptor for nitric oxide (NO), is a heterodimer consisting of two subunits, the α and the ß subunit. The NO/sGC/cGMP signaling pathway is protective in different disease pathomechanisms including angina pectoris, pulmonary hypertension and fibrotic diseases. The natural ligand heme has two carboxylic acids which interact in the ß1 heme nitric oxide oxygen binding (HNOX) domain with the amino acids of the highly conserved Y-x-S-x-R motif. The Y-x-S-x-R motif is also involved in binding of the dicarboxylic activators cinaciguat and BAY 60-2770 as indicated by crystallization studies of sGC activator and bacterial HNOX homologs. To what extent the Y-x-S-x-R motif hydrogen bond network contributes to binding of monocarboxylic acids has not been examined so far. In the current paper, the chemical structural formula of the novel monocarboxylic drug BAY-543 is described for the first time. Using this novel drug, we evaluate the importance of the amino acids Y135 and R139 for thermostabilization and activation in comparison to the dicarboxylic acid BAY 60-2770. Measurements with point mutated sGC variants demonstrate tyrosine 135 as exclusive binding site of the monocarboxylic acid BAY-543 but not the dicarboxylic BAY 60-2770.
Subject(s)
Enzyme Activators/pharmacology , Soluble Guanylyl Cyclase/metabolism , Amino Acid Motifs , Animals , Benzoates/metabolism , Benzoates/pharmacology , Binding Sites , Biphenyl Compounds/metabolism , Biphenyl Compounds/pharmacology , Enzyme Activation , Enzyme Activators/chemistry , Enzyme Activators/metabolism , HEK293 Cells , Humans , Hydrocarbons, Fluorinated/metabolism , Hydrocarbons, Fluorinated/pharmacology , Nitric Oxide/metabolism , Nitric Oxide/pharmacology , Point Mutation , Protein Binding , Protein Conformation , Protein Subunits , Sf9 Cells , Soluble Guanylyl Cyclase/chemistry , Soluble Guanylyl Cyclase/genetics , Structure-Activity Relationship , TyrosineABSTRACT
Thermal shift assay is a fluorescence dye based biochemical method to determine the melting point of a protein. It can be used to investigate the ligand-induced stabilization of proteins and helps to increase the likelihood of crystallization in biological samples. Dimeric proteins like soluble guanylyl cyclase (sGC) have specific structural and functional properties which may pose a challenge in thermal shift measurements. In this paper, thermal shift assay was used to examine ligand-induced thermostabilization of the dimeric heme-containing protein soluble guanylyl cyclase. Adjustment of the parameters buffer solution, pH, protein / dye ratio and protein amount per well yielded a one-phase melting curve of sGC with a sharp transition and high reproducibility. We found that thermal shift measurement is not affected by heme state or heme content of the enzyme preparation. We used the method to investigate the thermostabilization of sGC induced by the heme-mimetic activator drugs cinaciguat, BAY 60-2770 and BR 11257 in combination with non-hydrolyzable nucleotides. Measurements with the dicarboxylic drugs cinaciguat and BAY 60-2770 yielded steep melting curves with high amplitudes. In contrast, in the presence of the monocarboxylic sGC activator BR 11257, melting curves appear flattened in the dye-based measurements. In the present paper, we show that activity-based thermostability measurements are superior to dye-based measurements in detecting the thermostabilizing influence of sGC activator drugs.
Subject(s)
Differential Thermal Analysis/methods , Enzyme Stability/drug effects , Soluble Guanylyl Cyclase/chemistry , Benzoates/pharmacology , Biphenyl Compounds/pharmacology , Hydrocarbons, Fluorinated/pharmacology , Ligands , Nucleotides/pharmacology , Transition TemperatureABSTRACT
The soluble guanylyl cyclase (sGC) plays a key role in NO/cGMP signalling and is widely recognised to be important in different disease pathomechanisms. The discovery of sGC agonists provides a new opportunity to stimulate the NO/cGMP pathway. One class of compounds are the heme-independent sGC activators, which are thought to bind to oxidised or heme-free sGC. This enzyme is preferentially formed under disease situations accompanied by oxidative stress. Accordingly, this binding mode of sGC activators has quite some appeal for the clinical use of sGC activator drugs in diseases with high oxidative stress burden. However, none of the previous sGC activators, most of them dicarboxylic acid derivatives, has passed clinical trials to date, also because of the potent blood pressure lowering effects. In the current study, we investigate the effects of a new monocarboxylic drug BR 11257 in vitro and in vivo. Activity measurements with purified enzyme indicated gentle sGC activation for BR 11257 resembling a partial agonistic behaviour. In thermal shift measurements, we observed an unexpected difference between BR 11257 and the sGC activators from the dicarboxylic acid type. While activators from the dicarboxylic acid type had a highly thermostabilising influence on sGC, this effect was absent with BR 11257. We hypothesize that the key interaction partner for thermostabilisation is the second carboxylic acid in BAY 60-2770 which is missing in BR 11257. The absence of this thermodynamic receptor stabilisation and the partial agonism may be advantageous to overcome limitations of this class of drugs by avoiding excessive hypotension.
Subject(s)
Benzoates/pharmacology , Biphenyl Compounds/pharmacology , Drug Partial Agonism , Enzyme Activators/pharmacology , Hydrocarbons, Fluorinated/pharmacology , Soluble Guanylyl Cyclase/metabolism , Animals , Benzoates/chemistry , Biphenyl Compounds/chemistry , Cell Line , Dose-Response Relationship, Drug , Enzyme Activation/drug effects , Enzyme Activation/physiology , Enzyme Activators/chemistry , Humans , Hydrocarbons, Fluorinated/chemistry , Insecta , Male , Rats , Rats, WistarABSTRACT
Soluble guanylyl cyclase (sGC) is a heterodimeric enzyme consisting of one α and one ß subunit. The α1ß1 (GC-1) and α2ß1 (GC-2) heterodimers are important for NO signaling in humans and catalyse the conversion from GTP to cGMP. Each sGC subunit consists of four domains. Several crystal structures of the isolated domains are available. However, crystals of full-length sGC have failed to materialise. In consequence, the detailed three dimensional structure of sGC remains unknown to date. Different techniques including stopped-flow spectroscopy, Förster-resonance energy transfer, direct fluorescence, analytical ultracentrifugation, chemical cross-linking, small-angle X-ray scattering, electron microscopy, hydrogen-deuterium exchange and protein thermal shift assays, were used to collect indirect information. Taken together, this circumstantial evidence from different groups brings forth a plausible model of sGC domain arrangement, spatial orientation and dynamic rearrangement upon activation. For analysis of the active conformation the stable binding mode of sGC activators has a significant methodological advantage over the transient, elusive, complex and highly concentration dependent effects of NO in many applications. The methods used and the results obtained are reviewed and discussed in this article.
ABSTRACT
Nitric oxide sensitive guanylyl cyclase (NOsGC) is a heterodimeric enzyme consisting of one α and one ß subunit. Each subunit consists of four domains: the N-terminal heme-nitric oxide oxygen binding (HNOX) domain, a PAS domain, a coiled-coil domain and the C-terminal catalytic domain. Upon activation by the endogenous ligand NO or activating drugs, NOsGC catalyses the conversion of GTP to cGMP. Although several crystal structures of the isolated domains are known, the structure of the full-length enzyme and the interdomain conformational changes during activation remain unsolved to date. In the current study, we performed protein thermal shift assays of purified NOsGC to identify discrete conformational states amenable to further analysis e.g. by crystallisation. A non-hydrolysable substrate analogue binding to the catalytic domain led to a subtle change in melting temperature. An activator drug binding to the HNOX domain led to a small increase. However, the combination of substrate analogue and activator drug led to a marked synergistic increase from 51⯰C to 60⯰C. This suggests reciprocal communication between HNOX domain and catalytic domain and formation of a stable activated conformation amenable to further biophysical characterization.
Subject(s)
Benzoates/pharmacology , Enzyme Activators/pharmacology , Guanosine Triphosphate/pharmacology , Heme/metabolism , Soluble Guanylyl Cyclase/metabolism , Binding Sites , Catalytic Domain , Chlorides/pharmacology , Cyclic GMP/metabolism , Dose-Response Relationship, Drug , Drug Synergism , Enzyme Activation , Enzyme Stability , Guanosine Triphosphate/analogs & derivatives , Guanosine Triphosphate/metabolism , Heme/chemistry , Humans , Manganese Compounds/pharmacology , Protein Binding , Protein Conformation , Protein Denaturation , Soluble Guanylyl Cyclase/chemistry , Soluble Guanylyl Cyclase/genetics , Structure-Activity Relationship , Transition TemperatureABSTRACT
Hyperforin is a major active constituent of Hypericum perforatum (St. John's wort). It has amazing pharmacological activities, such as antidepressant properties, but it is labile and difficult to synthesize. Its sensitivity and lipophilicity are challenges for processing and formulation. Its chemical complexity provokes approaches of biotechnological production and modification. Dedifferentiated H. perforatum cell cultures lack appropriate storage sites and hence appreciable hyperforin levels. Shoot cultures are capable of forming hyperforin but less suitable for biomass up-scaling in bioreactors. Roots commonly lack hyperforin but a recently established adventitious root line has been demonstrated to produce hyperforin and derivatives at promising levels. The roots also contained lupulones, the typical constituents of hop (Humulus lupulus). Although shear-sensitive, these root cultures provide a potential production platform for both individual compounds and extracts with novel combinations of constituents and pharmacological activities. Besides in vitro cultivation techniques, the reconstruction of hyperforin biosynthesis in microorganisms is a promising alternative for biotechnological production. The biosynthetic pathway is under study, with omics-technologies being increasingly implemented. These biotechnological approaches may not only yield hyperforin at reasonable productivity but also allow for modifications of its chemical structure and pharmacological profile.
Subject(s)
Drug Compounding/methods , Hypericum , Phloroglucinol/analogs & derivatives , Plant Extracts/chemical synthesis , Technology, Pharmaceutical/methods , Terpenes/chemical synthesis , Biotechnology , Phloroglucinol/chemical synthesis , Phloroglucinol/isolation & purification , Plant Components, Aerial , Plant Extracts/isolation & purification , Plant Roots , Terpenes/isolation & purificationABSTRACT
Nitric oxide sensitive guanylyl cyclase (NOsGC), a hemoprotein and the major physiological receptor for nitric oxide (NO), is a heterodimer with the α1/ß1 and α2/ß1 isoforms known to be important for NO-signaling and conversion of GTP to cGMP in humans. Two innovative classes of compounds modulating the NO/cGMP signaling pathway have been discovered: the heme-dependent sGC stimulators, that stimulate NOsGC directly and also increase the affinity towards NO, and the heme-independent sGC activators, that are thought to bind to oxidized and heme-free NOsGC in tissues exposed to oxidative stress. In the current study, we evaluate the effects of the sGC activators BAY 58-2667 (cinaciguat) and BAY 60-2770 on the isoforms α1/ß1 and α2/ß1 expressed in Sf9 cells. Western blot analysis of cytosolic fractions revealed a decrease in overexpressed NOsGC in the presence of sGC activators, which is dependent on an intact catalytic site of the enzyme. For both isoforms, we show a higher efficacy for BAY 60-2770 compared to cinaciguat after purification of NOsGC by affinity and size exclusion chromatography. Using a new experimental strategy of expression of NOsGC with activator and subsequent purification, we demonstrate a stable insertion of activator drugs into the enzyme during protein biosynthesis independent of the heme redox state. We postulate that the balance between stable insertion of activator during de novo synthesis and replacement of NOsGC ferric heme in tissues exposed to oxidative stress can be influenced by the dosage regimen.
Subject(s)
Benzoates/metabolism , Biphenyl Compounds/metabolism , Enzyme Activators/metabolism , Hydrocarbons, Fluorinated/metabolism , Soluble Guanylyl Cyclase/metabolism , Amino Acid Sequence , Animals , Benzoates/pharmacology , Biphenyl Compounds/pharmacology , Dose-Response Relationship, Drug , Enzyme Activators/pharmacology , Humans , Hydrocarbons, Fluorinated/pharmacology , Isoenzymes/genetics , Isoenzymes/metabolism , Sf9 Cells , Soluble Guanylyl Cyclase/genetics , SpodopteraABSTRACT
Nitric oxide-sensitive guanylyl cyclase is a heterodimeric enzyme consisting of an α and a ß subunit. Two different α subunits (α1 and α2) give rise to two heterodimeric enzymes α1/ß1 and α2/ß1. Both coexist in a wide range of tissues including blood vessels and the lung, but expression of the α2/ß1 form is generally much lower and approaches levels similar to the α1/ß1 form in the brain only. In the present paper, we show that the α2/ß1 form interacts with Lin7a in mouse brain synaptosomes based on co-precipitation analysis. In HEK293 cells, we found that the overexpressed α2/ß1 form, but not the α1/ß1 form is directed to calcium-insensitive cell-cell contacts. The isolated PDZ binding motif of an amino-terminally truncated α2 subunit was sufficient for cell-cell contact localization. For the full length α2 subunit with the PDZ binding motif this was only the case in the heterodimer configuration with the ß1 subunit, but not as isolated α2 subunit. We conclude that the PDZ binding motif of the α2 subunit is only accessible in the heterodimer conformation of the mature nitric oxide-sensitive enzyme. Interaction with Lin7a, a small scaffold protein important for synaptic function and cell polarity, can direct this complex to nectin based cell-cell contacts via MPP3 in HEK293 cells. We conclude that heterodimerization is a prerequisite for further protein-protein interactions that direct the α2/ß1 form to strategic sites of the cell membrane with adjacent neighbouring cells. Drugs increasing the nitric oxide-sensitivity of this specific form may be particularly effective.
Subject(s)
Calcium/metabolism , Gene Expression Regulation, Enzymologic/physiology , Membrane Proteins/metabolism , Soluble Guanylyl Cyclase/metabolism , Animals , Female , HEK293 Cells , Humans , Membrane Proteins/genetics , Mice , Nitric Oxide , Protein Subunits , Protein Transport/physiology , Vesicular Transport ProteinsABSTRACT
In plants, prenylation of metabolites is widely distributed to generate compounds with efficient defense potential and distinct pharmacological activities profitable to human health. Prenylated compounds are formed by members of the prenyltransferase (PT) superfamily, which catalyze the addition of prenyl moieties to a variety of acceptor molecules. Cell cultures of Hypericum calycinum respond to elicitor treatment with the accumulation of the prenylated xanthone hyperxanthone E. A cDNA encoding a membrane-bound PT (HcPT) was isolated from a subtracted cDNA library and transcript preparations of H. calycinum. An increase in the HcPT transcript level preceded hyperxanthone E accumulation in cell cultures of H. calycinum treated with elicitor. The HcPT cDNA was functionally characterized by expression in baculovirus-infected insect cells. The recombinant enzyme catalyzed biosynthesis of 1,3,6,7-tetrahydroxy-8-prenylxanthone through regiospecific C-8 prenylation of 1,3,6,7-tetrahydroxyxanthone, indicating its involvement in hyperxanthone E formation. The enzymatic product shared significant structural features with the previously reported cholinesterase inhibitor γ-mangostin. Thus, our findings may offer a chance for semisynthesis of new active agents to be involved in the treatment of Alzheimer's disease.
Subject(s)
Cloning, Molecular/methods , Dimethylallyltranstransferase/genetics , Hypericum/enzymology , Dimethylallyltranstransferase/chemistry , Dimethylallyltranstransferase/metabolism , Gene Library , Hypericum/genetics , Models, Molecular , Plant Proteins/chemistry , Plant Proteins/genetics , Plant Proteins/metabolism , Protein Conformation , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Xanthones/metabolismABSTRACT
The complete structure of the assembled domains of nitric oxide-sensitive guanylate cyclase (NOsGC) remains to be determined. It is also unknown how binding of NO to heme in guanylate cyclase is communicated to the catalytic domain. In the current study the conformational change of guanylate cyclase on activation by NO was studied using FRET. Endogenous tryptophan residues were used as donors, the substrate analog 2'-Mant-3'-dGTP as acceptor. The enzyme contains five tryptophan residues distributed evenly over all four functional domains. This provides a unique opportunity to detect the movement of the functional domains relative to the substrate-binding catalytic region. FRET measurements indicate that NO brings tryptophan 22 in the αB helix of the ß1 heme NO binding domain and tryptophan 466 in the second short helix of the α1 coiled-coil domain closer to the catalytic domain. We propose that the respective domains act as a pair of tongs forcing the catalytic domain into the nitric oxide-activated conformation.
Subject(s)
Guanylate Cyclase/chemistry , Heme/chemistry , Nitric Oxide/chemistry , Receptors, Cytoplasmic and Nuclear/chemistry , Enzyme Activation , Guanylate Cyclase/genetics , Guanylate Cyclase/metabolism , Heme/genetics , Heme/metabolism , Humans , Nitric Oxide/genetics , Nitric Oxide/metabolism , Protein Structure, Secondary , Protein Structure, Tertiary , Receptors, Cytoplasmic and Nuclear/genetics , Receptors, Cytoplasmic and Nuclear/metabolism , Soluble Guanylyl CyclaseABSTRACT
Nitric-oxide-sensitive guanylyl cyclase (NO-sGC) plays a pivotal role in many second messenger cascades. Neurotransmission- and neuropathology-related changes in NO-sGC have been suggested. However, the cellular localization of NO-sGC in primate brains, including humans, remains unknown. Biochemical evidence has linked the alpha(2)-subunit of NO-sGC directly to neurotransmission in rodents. Here, we have used a recently characterized subunit-specific antibody for the localization of the alpha(2)-subunit on sections from the cerebelli of the common marmoset (Callithrix jacchus; New World monkey) and macaque monkeys (Macaca mulatta, M. fascicularis; Old World monkeys). In contrast to the more ubiquitous cytoplasmic presence of subunit-beta(1), the alpha(2)-subunit is mainly confined to the somato-dendritic membrane including the spines of the Purkinje cells. Only limited colocalization with presynaptically localized synaptophysin has been seen under our staining conditions, indicating a higher abundance of subunit-alpha(2) at the postsynaptic site. This localization indicates that subunit-alpha(2) links NO-sGC to neurotransmission, whereas subunit-beta(1) may act as a cytoplasmic regulator/activator by contributing to active heterodimer formation via translocation from the cytoplasm to the cell membrane. The last-mentioned action may be a prerequisite for generating nitric-oxide-dependent, subcellular, and postsynaptically localized cGMP signals along neuronal processes.
Subject(s)
Cerebellum/enzymology , Cerebellum/metabolism , Guanylate Cyclase/metabolism , Primates/metabolism , Protein Subunits/metabolism , Receptors, Cytoplasmic and Nuclear/metabolism , Animals , Antibodies, Monoclonal/metabolism , Calbindins , Callithrix , Cerebellum/cytology , Cyclic GMP/physiology , Guanylate Cyclase/genetics , Immunohistochemistry , Macaca fascicularis , Macaca mulatta , Male , Protein Subunits/genetics , Purkinje Cells/enzymology , Receptors, Cytoplasmic and Nuclear/genetics , S100 Calcium Binding Protein G/metabolism , Signal Transduction/physiology , Soluble Guanylyl Cyclase , Species SpecificityABSTRACT
Soluble guanylate cyclase (sGC) is a heterodimeric, nitric oxide (NO)-sensing hemoprotein composed of two subunits, alpha1 and beta1. NO binds to the heme cofactor in the beta1 subunit, forming a five-coordinate NO complex that activates the enzyme several hundred-fold. In this paper, the heme domain has been localized to the N-terminal 194 residues of the beta1 subunit. This fragment represents the smallest construct of the beta1 subunit that retains the ligand-binding characteristics of the native enzyme, namely, tight affinity for NO and no observable binding of O(2). A functional heme domain from the rat beta2 subunit has been localized to the first 217 amino acids beta2(1-217). These proteins are approximately 40% identical to the rat beta1 heme domain and form five-coordinate, low-spin NO complexes and six-coordinate, low-spin CO complexes. Similar to sGC, these constructs have a weak Fe-His stretch [208 and 207 cm(-)(1) for beta1(1-194) and beta2(1-217), respectively]. beta2(1-217) forms a CO complex that is very similar to sGC and has a high nu(CO) stretching frequency at 1994 cm(-)(1). The autoxidation rate of beta1(1-194) was 0.073/min, while the beta2(1-217) was substantially more stable in the ferrous form with an autoxidation rate of 0.003/min at 37 degrees C. This paper has identified and characterized the minimum functional ligand-binding heme domain derived from sGC, providing key details toward a comprehensive characterization.
Subject(s)
Guanylate Cyclase/chemistry , Heme/chemistry , Protein Conformation , Amino Acid Sequence , Animals , Guanylate Cyclase/genetics , Guanylate Cyclase/metabolism , Heme/genetics , Heme/metabolism , Humans , Models, Molecular , Molecular Sequence Data , Nitric Oxide/metabolism , Oxidation-Reduction , Protein Subunits/chemistry , Protein Subunits/genetics , Protein Subunits/metabolism , Rats , Sequence Alignment , Solubility , Spectrum Analysis, RamanABSTRACT
Possible differences in the localization of the cGMP response were investigated in rat brain coronal slices after in vitro incubation and NO-dependent or NO-independent stimulation of soluble guanylyl cyclase (sGC). Dose-dependent stimulation of cGMP synthesis by the NO donors, sodium nitroprusside, S-nitrosoglutathione, 3-morpholinosydnonimine and diethylamino NONOate was studied in the somatoparietal cortex, the hippocampus and the thalamus. cGMP accumulation was evaluated using a radioimmunoassay and by measuring cGMP-immunofluorescence using image analysis. All four NO donors induced similar cGMP staining patterns in the somatoparietal cortex, the hippocampus and the thalamus. NO-mediated cGMP synthesis in the cortical areas colocalized predominantly with the acetylcholine transporter and occasionally with parvalbumin (GABAergic cells) or the neuronal glutamate transporter. Incubation of the slices in the combined presence of a NO donor and the NO-independent activators YC-1 or BAY 41-2272 strongly potentiated cGMP synthesis and induced abundant cGMP-immunoreactivity in cortical GABAergic and glutamatergic cells. These findings indicate that the mechanism of NO release from the NO donors used does not determine the location of the cGMP response. The results suggest that YC-1 and BAY 41-2272 trigger a NO-sensing mechanism in cells in which the sGC is otherwise not sensitive to NO.
Subject(s)
Cyclic GMP/metabolism , Neurons/metabolism , Nitric Oxide/metabolism , Prosencephalon/metabolism , Receptors, Cytoplasmic and Nuclear/metabolism , Amino Acid Transport System X-AG/metabolism , Animals , Enzyme Activators/pharmacology , Glutamic Acid/metabolism , Guanylate Cyclase , Immunohistochemistry , Male , Membrane Transport Proteins/metabolism , Neurons/drug effects , Nitric Oxide Donors/pharmacology , Organ Culture Techniques , Parvalbumins/metabolism , Prosencephalon/anatomy & histology , Prosencephalon/drug effects , Rats , Rats, Inbred Lew , Receptors, Cytoplasmic and Nuclear/agonists , Second Messenger Systems/drug effects , Second Messenger Systems/physiology , Soluble Guanylyl Cyclase , Synaptic Transmission/drug effects , Synaptic Transmission/physiology , Vesicular Acetylcholine Transport Proteins , gamma-Aminobutyric Acid/metabolismABSTRACT
BACKGROUND: Nitric oxide (NO) mediates different cellular functions by activating soluble guanylate cyclase (sGC) that converts guanosine-5'-triphosphate (GTP) to cyclic guanosine-3',5'-monophosphate (cGMP). Membrane-bound GCs produce cGMP in response to natriuretic peptides in osteoblasts, but neither the NO-target enzyme sGC, nor the phosphorylation sites of NOS III, nor their regulation by extracellular signal-regulated kinases 1 and 2 (ERK1/2) and Akt/protein kinase B (Akt/PKB) in osteoclasts have been established. METHODS: Rat molars with periodontium were perfusion- and post-fixed, decalcified, and frozen-sectioned. Free-floating sections were stained using nicotinamide adenine dinucleotide phosphate-diaphorase (NADPH-d) and tartrate-resistant acid phosphatase (TRAP) histochemical techniques and immunoreacted with antisera against NO-synthase (NOS) I-III, NOS III phoshorylated at Thr495, NOS III phoshorylated at Serine1177 (Ser1177), ERK1/2, phosphorylated ERK1/2, Akt/PKB, phosphorylated Akt/PKB, sGC (alpha2/beta1), and cGMP. RESULTS: NADPH-d staining and immunostaining of NOS I-III, NOS III phosphorylated at Ser1177, ERK1/2, Akt/PKB, phosphorylated Akt/PKB, sGC (alpha2 and beta1-subunits), and cGMP were detected in osteoclasts. Immunohistochemical reaction products for NOS III phosphorylated at threonine495 (Thr495) and phosphorylated ERK1/2 could not be identified in osteoclasts. Comparison of TRAP activity and immunostaining for sGC beta1-subunit revealed that sGC beta1-subunit is only expressed in a sub-population of osteoclasts. CONCLUSIONS: NO is likely to be generated by NOS I and NOS III in osteoclasts. The inconstant expression of NOS II in some osteoclasts may be explained with inducible expression of NOS II upon physiological cell activation. Localization of the sGC alpha2- and beta1-subunits and cGMP in osteoclasts is compatible with an involvement of NO-sGC signaling in the homeostasis of osteoclasts. The phosphorylation site of NOS III at Ser1177 and phosphorylated Akt/PKB are involved in regulation of NO production by NOS III in osteoclasts under basal conditions.
Subject(s)
Alveolar Process/cytology , Nitric Oxide Synthase/metabolism , Nitric Oxide/metabolism , Osteoclasts/enzymology , Second Messenger Systems , Alveolar Process/enzymology , Animals , Cyclic GMP/biosynthesis , Guanylate Cyclase/metabolism , Immunoenzyme Techniques , Male , Phosphorylation , Protein Serine-Threonine Kinases/metabolism , Rats , Rats, WistarABSTRACT
Soluble guanylyl cylase (sGC) has been identified for being a receptor for the gaseous transmitters nitric oxide and carbon monoxide. Currently four subunits alpha1, alpha2, beta1, and beta2 have been characterized. Heterodimers of alpha and beta-subunits as well as homodimers of the beta2-subunit are known to constitute functional sGC which use GTP to form cGMP a potent signal molecule in a multitude of second messenger cascades. Since NO-cGMP signaling plays a pivotal role in neuronal development we analyzed the maturational expression pattern of the newly characterized alpha2-subunit of sGC within the brain of Wistar rats by means of RNase protection assay and immunohistochemistry. alpha2-subunit mRNA as well as immunoreactive alpha2-protein increased during postnatal cerebral development. Topographical analysis revealed a selective high expression of the alpha2-subunit in the choroid plexus and within developing sensory systems involving the olfactory and somatosensory system of the forebrain as well as parts of the auditory and visual system within the hindbrain. In cultured cortical neurons the alpha2-subunit was localized to the cell membrane, especially along neuronal processes. During the first 11 days of postnatal development several cerebral regions showed a distinct expression of the alpha2-subunit which was not paralleled by the alpha1/beta1-subunits especially within the developing thalamo-cortical circuitries of the somatosensory system. However, at later developmental stages all three subunits became more homogenously distributed among most cerebral regions, indicating that functional alpha1/beta1 and alpha2/beta1 heterodimers of sGC could be formed. Our findings indicate that the alpha2-subunit is an essential developmentally regulated constituent of cerebral sensory systems during maturation. In addition the alpha2-subunit may serve other functions than forming a functional heterodimer of sGC during the early phases of sensory pathway refinement.
Subject(s)
Brain/enzymology , Brain/growth & development , Neural Pathways/growth & development , Receptors, Cytoplasmic and Nuclear/biosynthesis , Aging/physiology , Animals , Brain/cytology , Cell Nucleus/enzymology , Cells, Cultured , Guanylate Cyclase , Immunohistochemistry , Male , Neural Pathways/cytology , Neurons/enzymology , Neuropil/enzymology , Nitric Oxide Synthase/biosynthesis , Nitric Oxide Synthase Type II , Nuclease Protection Assays , RNA Probes , RNA, Messenger/biosynthesis , Rats , Rats, Wistar , Reverse Transcriptase Polymerase Chain Reaction , Soluble Guanylyl CyclaseABSTRACT
The aim of the study was to compare the localization of the nitric oxide (NO)-cGMP pathway in hippocampus of mice and rats using cGMP- and soluble guanylyl cyclase (GC) immunocytochemistry and in situ hybridization of the cGMP-hydrolysing phosphodiesterase types 2, 5 and 9. In vitro incubation of hippocampus slices in the absence of a guanylyl cyclase stimulator or a phosphodiesterase inhibitor resulted in cGMP-positive astrocytes mainly in the CA1 area in mouse slices. In contrast, no cGMP immunoreactivity was observed under these conditions in the rat hippocampus. Treatment with an NO synthase inhibitor or inhibitors of soluble or particulate GC did not abolish cGMP immunoreactivity in astrocytes. Incubation with the NO donors sodium nitroprusside or diethylamino NONOate, or with the NO-independent activators of soluble GC, YC-1 and BAY 41-2272, in combination with phosphodiesterase inhibitors, resulted in an increase in cGMP immunoreactivity in numerous astrocytes throughout the mouse hippocampus. In contrast, under these conditions cGMP immunoreactivity was primarily observed in varicose fibers in rat hippocampus. Comparison of the cellular localization of the beta1 subunit of soluble GC and the mRNAs of PDE2, PDE5 and PDE9 revealed that in both species the beta1 subunit was observed in pyramidal and granule cells, which also expressed the mRNAs of the three phosphodiesterase families. Although the beta1 subunit was observed in astrocytes, none of the phosphodiesterases were detected in these cells. We conclude that, although the expression profiles of the soluble GC beta1 subunit and cGMP-hydrolysing phosphodiesterase mRNAs were identical, the cellular patterns of cGMP immunoreactivity differ between rat and mouse hippocampus.
Subject(s)
Cyclic GMP/biosynthesis , Hippocampus/chemistry , Nitric Oxide/physiology , Animals , Cyclic GMP/analysis , Hippocampus/drug effects , Hippocampus/metabolism , Immunohistochemistry , Mice , Mice, Inbred C57BL , Nitric Oxide Donors/pharmacology , Phosphodiesterase Inhibitors/pharmacology , Phosphoric Diester Hydrolases/analysis , Phosphoric Diester Hydrolases/biosynthesis , Rats , Rats, Inbred Lew , Signal Transduction/physiology , Species SpecificityABSTRACT
The only published report of the purification of native human soluble guanylyl cyclase (sGC) used placenta as starting material. This enzyme preparation showed low fold-activation by NO and a maximal absorption of the prosthetic heme-group at 417nm indicative of a prosthetic heme-group in a hexa-coordinate state. These data are in contrast to what has subsequently been found for the recombinant human enzymes. Apart from this placental enzyme preparation, a native functional human NO-sensitive sGC has not been successfully purified. The aim of the current study was to purify and characterize native human sGC from another source, to see whether the discrepancies between native and recombinant sGC seen for placenta are a general phenomenon. We chose human platelets as starting material since the properties of this enzyme are directly relevant for the development of innovative antiplatelet and antianginal drugs. Our results indicate that the native platelet enzyme exists as a highly NO-sensitive, heterodimeric enzyme with an alpha(1) and beta(1) subunit. In contrast to the native human placental enzyme and in accordance with the human recombinant enzymes, the native human platelet enzyme contains a ferrous, penta-coordinate heme group. To our knowledge this is the first report of the successful purification and characterization of the native human nitric oxide sensitive alpha(1)/beta(1) isoform of sGC which is widely expressed in the cardiovascular system and is an important target of innovative drugs.
Subject(s)
Blood Platelets/enzymology , Guanylate Cyclase/isolation & purification , Isoenzymes/isolation & purification , Nitric Oxide/metabolism , Cyclic GMP/metabolism , Guanylate Cyclase/metabolism , Humans , Isoenzymes/metabolism , Substrate SpecificityABSTRACT
The epithelial rests of Malassez (ERM) are derived from the disintegrating epithelial root sheath of Hertwig that guides root formation during tooth development. Low concentrations of nitric oxide (NO) produced by NO-synthase I (NOS I) and NOS III activate intracellular soluble guanylate cyclase (sGC) to produce intracellular cyclic guanosine 3':5'-monophosphate (cGMP), which triggers rapid cellular responses such as cell proliferation, cell differentiation, and apoptosis under physiological conditions. The presence of NOS I-III, sGC (alpha2- and beta1-subunits) and cGMP in the ERM was investigated by immunohistochemistry. Rat molars with periodontium were perfusion and postfixed, decalcified, frozen-sectioned, and sections were immunostained. NOS I, NOS III, sGC (alpha2- and beta1-subunits) and cGMP were localized with different densities in the ERM. The presence of NOS II in the ERM varied. The localization of NOS I, NOS III, sGC and cGMP in the ERM indicates an involvement of NO and/or NO-cGMP signal pathway molecules in homeostasis of a variety of physiological processes in the ERM. These could include regulation of cell proliferation, cell differentiation and apoptosis.